First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

@article{RuZMorales2016FirstlineSV,
  title={First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.},
  author={Jos{\'e} Manuel Ru{\'i}Z-Morales and Marcin Świerkowski and Jonatan C. Wells and Anna Paola Fraccon and Felice Pasini and Frede N. Donskov and G A Georg Bjarnason and J Y Lee and Hao-Wen Sim and Andrzej Sliwczynsk and Aneta Ptak-Chmielewska and Zbigniew Teter and B Beuselinck and Lori A. Wood and Takeshi Yuasa and Carmel Jo Pezaro and Brian I. Rini and Cezary A. Szczylik and Toni K Choueiri and Daniel Yick Chin Heng},
  journal={European journal of cancer},
  year={2016},
  volume={65},
  pages={102-8}
}
BACKGROUND Sunitinib (SU) and pazopanib (PZ) are standards of care for first-line treatment of metastatic renal cell carcinoma (mRCC). However, how the efficacy of these drugs translates into effectiveness on a population-based level is unknown. PATIENTS AND METHODS We used the International mRCC Database Consortium (IMDC) to assess overall survival (OS), progression-free survival (PFS), response rate (RR) and performed proportional hazard regression adjusting for IMDC prognostic groups… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 30 times over the past 90 days. VIEW TWEETS
7 Citations
0 References
Similar Papers

Similar Papers

Loading similar papers…